Compare

FibroBiologics, Inc. vs Cocrystal Pharma, Inc. vs Can-Fite BioPharma Ltd. vs Nanoviricides, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearFibroBiologics, Inc.
FBLG
Cocrystal Pharma, Inc.
COCP
Can-Fite BioPharma Ltd.
CANF
Nanoviricides, Inc.
NNVC
Year ended2025-12-312025-12-312025-12-312026-06-30
Revenuen/an/a$405.0K$0
Revenue growth (YoY)n/an/a-39.9%n/a
Gross marginn/an/an/an/a
Operating marginn/an/an/mn/a
Net marginn/an/an/mn/a
Net income-$18.65M-$8.83M-$9.83M-$8.22M
EPS (Diluted)-$0.42-$0.78-$5.97-$0.41
Operating cash flow-$16.39M-$8.19M-$8.95M-$7.70M
Free cash flow-$16.66M-$8.20M-$8.95M-$7.78M
Cash & equivalents$4.89M$7.03M$5.53M$2.79M
Total assets$9.62M$9.71M$9.51M$9.87M
Total liabilities$3.46M$3.38Mn/a$1.20M
Shareholders' equity$6.16M$6.33M$5.59M$8.68M
Return on year-end equity-302.9%-139.5%-175.8%-94.7%
Shares outstandingn/a13.78M2.62M23.01M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearFibroBiologics, Inc.Cocrystal Pharma, Inc.Can-Fite BioPharma Ltd.Nanoviricides, Inc.
Latestn/a$2.01M
Ended 2020-12-31
$405.0K
Ended 2025-12-31
$0
Ended 2026-06-30
1 year earliern/a$6.56M
Ended 2019-12-31
$674.0K
Ended 2024-12-31
$0
Ended 2025-06-30
2 years earliern/an/a$743.0K
Ended 2023-12-31
$0
Ended 2024-06-30
3 years earliern/an/a$810.0K
Ended 2022-12-31
$0
Ended 2023-06-30
4 years earliern/an/a$853.0K
Ended 2021-12-31
n/a